Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Outcomes of HLA-matched unrelated donor versus haploidentical transplantation

Muhammad Umair Mushtaq • 17 Feb 2023
Tandem Meetings 2023
General Cyclophosphamide Methotrexate Tacrolimus

Muhammad Umair Mushtaq, MD, University of Kansas Medical Center, Westwood, KS, shares the results of a single-center retrospective study comparing the outcomes of 452 patients who underwent HLA-matched unrelated donor (MUD) and haploidentical hematopoietic cell transplantation (HCT). Overall, the study reported similar outcomes in terms of overall survival (OS), disease-free survival (DFS), relapse, non-relapse mortality (NRM), graft-versus-host disease (GvHD), and neutrophil engraftment between the two cohorts. A one-week delay in platelet engraftment was reported in haploidentical transplants. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Muhammad Umair Mushtaq

2:07
Outcomes with CD34-selected stem cell boost for poor graft function and graft failure after alloSCT
Muhammad Umair Mushtaq • 17 Feb 2023
2:09
Continuous IVIG and platelet transfusion for refractory AITP in patients undergoing alloSCT
Muhammad Umair Mushtaq • 17 Feb 2023
2:06
Immunogenicity of COVID-19 vaccination in transplant and CAR-T therapy recipients
Muhammad Umair Mushtaq • 25 Apr 2022
1:40
Outcomes of alloHSCT in TP53-mutated AML and MDS
Muhammad Umair Mushtaq • 25 Apr 2022

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:44
PHOEBUS trial: oral fecal microbiotherapy for increasing OS in patients undergoing alloSCT
Florent Malard • 11 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
3:29
PTCy as GvHD prophylaxis: side effects, optimizing the dose, and the effect of dose-reduction
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals